Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7NRF6
|
|||
| Drug Name |
HaNK
|
|||
| Drug Type |
Cell therapy
|
|||
| Indication | Merkel cell carcinoma [ICD-11: 2C34; ICD-10: C44] | Phase 2 | [1] | |
| Company |
ImmunityBio
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03853317) QUILT-3.063: A Phase 2 Study of Combination Therapy With an IL-15 Superagonist (N-803), Off-the-shelf CD16-targeted Natural Killer Cells (haNK), and Avelumab Without Cytotoxic Chemotherapy in Subjects With Merkel Cell Carcinoma (MCC) That Has Progressed on or After Treatment With a Checkpoint Inhibitor. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.